Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 2,098 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Lung Disease Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

NCT04722887
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 4:23 AM EDT
Withdrawn Not applicable Interventional

Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD

NCT03228121
View directory record Official record
Conditions
COPD, Emphysema or COPD, Chronic Bronchitis
Interventions
Treatment Then Placebo, Placebo Then Treatment
Procedure
Lead sponsor
Lung Institute
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Not applicable Interventional Results available

Family-supported Smoking Cessation for Chronically Ill Veterans

NCT00448344
View directory record Official record
Conditions
Chronic Disease, Neoplasm, Cardiovascular Disease, Pulmonary Disease, Chronic Obstructive, Diabetes Mellitus, Hypertension
Interventions
Family-supported, Standard Telephone counseling
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 15, 2026, 4:23 AM EDT
Recruiting No phase listed Observational

COPD Exacerbation Follow Up

NCT07118306
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Not listed
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
40 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Park Ridge, Illinois • Cherry Hill, New Jersey • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 4:23 AM EDT
Enrolling by invitation Not applicable Interventional

Virtual Nurse and Social Worker Palliative Care Team to Improve Quality of Life in Veterans With Heart Failure or COPD

NCT07714252
View directory record Official record
Conditions
Heart Failure, Pulmonary Disease, Chronic Obstructive, Interstitial Lung Disease
Interventions
Virtual Nurse and Social Worker Palliative Care Team, Enhanced Implementation Support, Standard Implementation Support
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

NCT04133909
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

Long-term Oxygen Treatment Trial

NCT00692198
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Supplemental oxygen therapy
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • Loma Linda, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Phase 2 Interventional

Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD

NCT00640484
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
carmoterol (CHF 4226), placebo, salmeterol
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 15, 2026, 4:23 AM EDT
Withdrawn No phase listed Observational

Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab

NCT03369574
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Asthma, Nasal Polyps
Interventions
Reslizumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 15, 2026, 4:23 AM EDT
Completed No phase listed Observational

Bion Occipital Nerve Stimulation (ONS) Compassionate Use Study

NCT01050959
View directory record Official record
Conditions
Chronic, Medically Refractory Headache
Interventions
bion
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Phoenix, Arizona • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Phase 4 Interventional

Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD

NCT03370835
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Asthma, Adverse Effect of Beta-adrenoreceptor Antagonists
Interventions
Metoprolol succinate ER, Carvedilol
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

NCT05592418
View directory record Official record
Conditions
Post COVID-19 Condition, Long COVID
Interventions
Rintatolimod, Placebo / Normal Saline
Drug · Other
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Canoga Park, California • Inglewood, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of RSLV-132 in Subjects With Long COVID

NCT04944121
View directory record Official record
Conditions
Post-acute Corona Virus 19 (COVID-19) (Long COVID)
Interventions
RSLV-132, Sodium Chloride 0.9%
Drug
Lead sponsor
Resolve Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Mobile, Alabama • Coral Gables, Florida • Pompano Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Not applicable Interventional Results available

Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial

NCT03277378
View directory record Official record
Conditions
Chronic, Intractable Pain of the Trunk and/or Lower Limbs
Interventions
lead placement followed by BurstDR stimulation
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Santa Rosa, California • Clearwater, Florida • Merritt Island, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Phase 2 Interventional

A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

NCT05672355
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, COVID-19 Infection
Interventions
Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Phase 2 Interventional

Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)

NCT02302417
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Spirometry, ACOS clinical questionnaire
Procedure · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
12
States / cities
Newport Beach, California • Upland, California • Sunset, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Not applicable Interventional

Indoor Air Quality and Respiratory Symptoms in Former Smokers

NCT02956213
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
HEPA portable air filter, Sham Control/Active Comparator
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
40 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 15, 2026, 4:23 AM EDT
Recruiting Phase 3 Interventional

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets

NCT07868419
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
NAL ER, Placebo
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Wilmington, Delaware • North Miami Beach, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 4:23 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

129Xe MRI Cardiopulmonary

NCT06038630
View directory record Official record
Conditions
Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism, Anemia, Polycythemia, Dyspnea
Interventions
Hyperpolarized Xe129, Oxygen Administration
Drug · Other
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Phase 1Phase 2 Interventional

Duration of Spinal Manipulation Effects as Influenced by Orthotics

NCT01704807
View directory record Official record
Conditions
Low Back Pain
Interventions
foot orthotics, Sham foot orthotic
Device
Lead sponsor
Logan College of Chiropractic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy for COPD

NCT01694628
View directory record Official record
Conditions
COPD, Depression
Interventions
CLIMB (COPD Lifestyle, Mood, and Behavior)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 15, 2026, 4:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
D. Walter Wray
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Not applicable Interventional

Rehabilitation of Patients With COPD Using Electrical Muscle Stimulation

NCT01799330
View directory record Official record
Conditions
COPD
Interventions
Transcutaneous Electrical Muscle Stimulation (TCEMS), Sham TCEMS
Procedure · Other
Lead sponsor
Yale University
Other
Eligibility
Up to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 15, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics

NCT02126839
View directory record Official record
Conditions
Asthma
Interventions
Albuterol MDPI, Placebo, ProAir HFA inhaler
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 15, 2026, 4:23 AM EDT